Cerebrolysin, 2 ml 10 pcs

Pharmacodynamics

Cerebrolysin contains low molecular weight biologically active neuropeptides that penetrate through the BBB and directly reach the nerve cells. The drug has an organ-specific multimodal effect on the brain, i.e. provides metabolic regulation, neuroprotection, functional neuromodulation and neurotrophic activity.

Metabolic regulation: Cerebrolysin increases the efficiency of aerobic energy metabolism of the brain, improves intracellular protein synthesis in the developing and aging brain.

Neuroprotection: Cerebrolysin protects neurons from the damaging effects of lactate acidosis, prevents the formation of free radicals, increases survival and prevents neuronal death in conditions of hypoxia and ischemia, reduces the damaging neurotoxic effects of excitatory amino acids (glutamate).

Neurotrophic activity: Cerebrolysin is the only nootropic peptidergic drug with proven neurotrophic activity similar to the action of natural neural growth factors (NGF), but manifested under peripheral administration.

Functional neuromodulation: Cerebrolysin has a positive effect in cognitive disorders, on memory processes.

Pharmacokinetics

The complex composition of Cerebrolysin, the active fraction of which consists of a balanced and stable mixture of biologically active oligopeptides with total multifunctional action, does not allow the usual pharmacokinetic analysis of individual components.

Indications

Stroke sequelae, Alzheimer’s disease, Mental retardation in children, Attention and memory disorders, Acquired dementia, Concussion and other brain injuries, Depression, Headaches, Asthenia, Learning disabilities.ul>

.

Active ingredient

Brain Peptide Complex

Composition

1 ml of solution for injection contains:

active ingredient:

Cerebrolysin concentrate (pig brain-derived peptide complex) 215.2 mg,

excipients:

sodium hydroxide;

water for injection

.

How to take, the dosage

Intramuscularly (up to 5 ml), intravenously (up to 10 ml), intravenously, by slow infusion (10 to 50 ml).

Doses and duration of treatment depend on the nature and severity of the disease, as well as the age of the patient. Single doses of up to 50 ml may be prescribed, but a course of treatment is preferable. The recommended optimal course of treatment is daily injections for 10-20 days.

Acute conditions (ischemic stroke, traumatic brain injury, complications after neurosurgical operations) – from 10 to 50 ml.

Residual period of cerebral stroke and traumatic brain and spinal cord injury – from 5 to 50 ml.

Psychoorganic syndrome and depression – 5 to 30 ml.

Alzheimer’s disease, dementia of vascular and combined Alzheimer’s-vascular genesis – 5 to 30 ml.

In neuropediatric practice, 0.1-0.2 ml/kg.

To increase the effectiveness of treatment, repeated courses may be given as long as there is improvement of the patient’s condition due to treatment. After the first course, the frequency of dosing may be reduced to 2 or 3 times per week.

Doses of 10 to 50 ml are recommended to be administered only by slow intravenous nfusions after dilution with the suggested standard solutions for infusion. The duration of infusions is 15 to 60 minutes.

Interaction

Taking into account the pharmacological profile of Cerebrolysin, special attention should be paid to possible additive effects when coadministered with antidepressants, including MAO inhibitors. In these cases it is recommended to reduce the dose of antidepressant.

Cerebrolysin and balanced amino acid solutions should not be mixed in the same infusion solution.

Cerebrolysin is not compatible with solutions that contain lipids and with pH-altering solutions (5-8).

Special Instructions

Compatibility of the drug has been tested and confirmed (for 24 hours at room temperature and lighting) with the following standard solutions for infusion:

– 0.9% sodium chloride solution (9 mg NaCl/ml);

– Ringer’s solution (Na+ – 153.98 mmol/L; Ca2+ – 2.74 mmol/L; K+ – 4.02 mmol/L; Cl- – 163.48 mmol/L).

– 5% glucose solution.

Cerebrolysin may be administered simultaneously with vitamins and drugs improving cardiac circulation, but these drugs should not be mixed in the same syringe with Cerebrolysin. Only the clear solution should be used and only once.

The effect on the ability to drive vehicles and operate machinery. Clinical trials have shown that Cerebrolysin has no effect on the ability to drive vehicles and operate machinery.

.

Contraindications

• individual intolerance to the drug
• acute renal failure
• Epileptic status.

.

Side effects

Reaction to administration: if administered too quickly, rarely a fever, sweating, dizziness; in isolated cases, palpitations or arrhythmias may occur. Therefore, the drug should be administered slowly.

Gastrointestinal disorders: rare – loss of appetite, dyspepsia, diarrhea, constipation, nausea and vomiting.

CNS and peripheral nervous system disorders: in rare cases, the presumed effect of activation was accompanied by agitation (manifested by aggressive behavior, confusion, insomnia). There have been reports of the occurrence in single cases (

On the immune system: extremely rare – hypersensitivity or allergic reactions, manifested by headache, pain in the neck, extremities, lower back, shortness of breath, chills and collaptoid condition.

Local reactions: rarely – redness of the skin, itching and burning at the injection site.

Others: extremely rare – cases of hyperventilation, arterial hypertension, arterial hypotension, fatigue, tremor, depression, apathy, dizziness and flu-like symptoms (cough, runny nose, respiratory infections) have been reported in studies.

Please note that some adverse effects (agitation, hypertension, hypotension, lethargy, tremor, depression, apathy, dizziness, headache, dyspnea, diarrhea, nausea) have been reported in clinical trials and occurred equally in patients receiving Cerebrolysin as in patients in the placebo group.

Pregnancy use

The drug is administered with caution in the first trimester of pregnancy and during lactation.

Cerebrolysin should only be used during pregnancy and lactation after careful analysis of the ratio of the positive effect of treatment to the risk associated with it.

The results of experimental studies do not suggest that Cerebrolysin has teratogenic effects or toxic effects on the fetus. However, similar clinical studies have not been performed.